These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21095196)

  • 1. Mutational and promoter hypermethylation status of FHIT gene in breast cancer patients of Kashmir.
    Syeed N; Husain SA; Sameer AS; Chowdhri NA; Siddiqi MA
    Mutat Res; 2011 Feb; 707(1-2):1-8. PubMed ID: 21095196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
    Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
    Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Fragile Histidine Triad gene and breast cancer.
    Yang Q; Yoshimura G; Sakurai T; Kakudo K
    Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
    Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
    Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
    Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
    Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
    Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Wang YL; Han LX; Jiang YW; Fei X; Cen JN; Chen ZX
    Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma.
    Tzao C; Sun GH; Tung HJ; Hsu HS; Hsu WH; Wang YC; Cheng YL; Lee SC
    Ann Thorac Surg; 2006 Aug; 82(2):396-401; discussion 401. PubMed ID: 16863736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
    Ismail HM; Medhat AM; Karim AM; Zakhary NI
    Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FHIT alterations in breast cancer.
    Ingvarsson S
    Semin Cancer Biol; 2001 Oct; 11(5):361-6. PubMed ID: 11562178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of the fragile histidine triad (FHIT) tumor suppressor gene in vesical tumors of cattle with chronic enzootic hematuria (CEH).
    Guidi E; Uboldi C; Ferretti L
    Cytogenet Genome Res; 2008; 120(1-2):173-7. PubMed ID: 18467844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East.
    Siraj AK; Ibrahim M; Al-Rasheed M; Bu R; Bavi P; Jehan Z; Abubaker J; Murad W; Al-Dayel F; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
    Ann Hematol; 2007 Dec; 86(12):887-95. PubMed ID: 17712558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
    Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
    Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
    Gatalica Z; Lele SM; Rampy BA; Norris BA
    Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FHIT expression and hypermethylation in esophageal squamous cell carcinoma.
    Noguchi T; Takeno S; Kimura Y; Uchida Y; Daa T; Yokoyama S; Gabbert HE; Mueller W
    Int J Mol Med; 2003 Apr; 11(4):441-7. PubMed ID: 12632095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.
    Zaki SM; Abdel-Azeez HA; El Nagar MR; Metwally KA; S Ahmed MM
    Asian Pac J Cancer Prev; 2015; 16(3):1235-9. PubMed ID: 25735361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FHIT gene at 3p14.2 is abnormal in breast carcinomas.
    Negrini M; Monaco C; Vorechovsky I; Ohta M; Druck T; Baffa R; Huebner K; Croce CM
    Cancer Res; 1996 Jul; 56(14):3173-9. PubMed ID: 8764101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.